Larimar Therapeutics (LRMR) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
MacroGenics (MGNX) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 97.0% versus a loss of 52.7%. Over five years, MGNX leads with a -83.0% price change compared with -84.5% for LRMR. MacroGenics is the larger company by market cap ($207.0 million vs $206.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | MGNX |
|---|---|---|
| Share price | $1.99 | $3.25 |
| Market cap | $206.21M | $207.03M |
| 1-day change | -0.25% | -3.56% |
| YTD return | -47.90% | +101.86% |
| 1-year return | -52.74% | +96.97% |
| 5-year return | -84.48% | -82.99% |
| EPS (TTM) | $-1.99 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $149.50M |
| Revenue growth (YoY) | — | -0.31% |
| Net income (latest FY) | $-165.67M | $-74.62M |
| Gross margin | — | 100.00% |
| Operating margin | — | -48.72% |
| Net margin | — | -49.91% |
| 52-week high | $6.42 | $5.08 |
| 52-week low | $1.92 | $1.29 |
| Distance from 52-week high | -69.08% | -36.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +625.44% | +146.15% |
| Average volume | 1.31M | 583.65K |
| Shares outstanding | 103.88M | 63.70M |
| Employees | 71 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed LRMR by 149.7 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
LRMR vs MGNX FAQ
Which is bigger, Larimar Therapeutics or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $207.03M compared with $206.21M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or MGNX?
MGNX returned +96.97% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.